Variation in Spending around Surgical Episodes of Urinary Stone Disease: Findings from Michigan.

PURPOSE: To help rein in surgical spending there is growing interest in the application of payment bundles to common outpatient procedures like ureteroscopy and shock wave lithotripsy. However, before urologists can move to such a payment system they need to know where episode costs are concentrated. MATERIALS AND METHODS: Using claims data from Michigan Value Collaborative we identified patients who underwent ureteroscopy or shock wave lithotripsy at hospitals in Michigan from 2012 to 2015. We then totaled expenditures for all relevant services during the 30-day surgical episodes of these patients and categorized component payments (ie those for the index procedure, subsequent hospitalizations, professional services and postacute care). Finally we quantified the variation in total episode expenditures for ureteroscopy and shock wave lithotripsy across hospitals, examining drivers of this variation. RESULTS: A total of 9,449 ureteroscopy and 6,446 shock wave lithotripsy procedures were performed at 62 hospitals. Among these hospitals there was threefold variation in ureteroscopy and shock wave lithotripsy spending. The index procedure accounted for the largest payment difference between high vs low cost hospitals (ureteroscopy $7,936 vs $4,995 and shock wave lithotripsy $4,832 vs $3,207, each p <0.01), followed by payments for postacute care (ureteroscopy $2,207 vs $1,711 and shock wave lithotripsy $2,138 vs $1,104, each p <0.01). Across hospitals the index procedure explained 68% and 44% of the variation in episode spending for ureteroscopy and shock wave lithotripsy, and postacute care payments explained 15% and 28%, respectively. CONCLUSIONS: There exists substantial variation in ambulatory surgical spending across Michigan hospitals for urinary stone episodes. Most of this variation can be explained by payment differences for the index procedure and for postacute care services.

Who "apparently" more spends, "in reality" spends less. Spending "a little" more for the rental of the extracorporeal lithotripter can save "a lot" about the days of hospitalization for urinary stones.

OBJECTIVE: The right to health (according to the Article 32 of the Italian Republic Constitution) is financially conditioned; for this reason the National Health System (NHS) has the objective of rationalize health expenditure according to the criteria of efficiency, effectiveness and economy. This paper is an example of rationalization concerning the extracorporeal shock wave lithotripsy (ESWL). MATERIALS AND METHODS: Hospital admissions for urinary stones were taken into account. "Edotto", the database of the Puglia region has identified 23 inpatient admissions during which was performed ESWL. A single operator performed ESWLs with a Storz lithotripter, Modulith SLK. RESULTS: The average hospital stay is conditioned by days "to wait" lithotripsy. In 2014 the hospitalization days "waiting for" lithotripsy were 100. The results were subjected to SWOT analysis and discussed with the Boston Consulting Group Matrix. DISCUSSION: Constant availability of the lithotripter would spare 100 days of hospitalization, amounting to € 88,200.00. This waste of resources corresponds to an additional cost equal to 98.3% on the cost for the rental of the lithotripter. Instead, reducing "unnecessary" hospitalization days would get a saving of 79.3% on the rental cost. It is as if for 46 days of the lithotripter rent were paid 46 days, while for 365 days of the lithotripter rent were paid only 11.8 sessions per year. CONCLUSIONS: Rationalization of resources is not necessarily a synonym of "reduction" of resources, but of reduction of waste in the NHS. A good plan is the most important rational basis to get more resources. About the process taken into account it is seen as an investment of € 21,450.00 would keep unchanged the effectiveness of lithotripsy service but would add efficiency and economy (increase of sessions/year, increase in the active mobility, increase in orthopedic treatments) and would drastically reduce the number hospital days (a waste).

Durability of reusable holmium:YAG laser fibers: a multicenter study.

PURPOSE: Single use and reusable variants of holmium:YAG laser fibers are available to treat calculi during ureteroscopic procedures. In this prospective, multicenter study we evaluated a series of reusable holmium:YAG laser optical fibers. We hypothesized that reusable fibers provide a cost advantage over single use variants. MATERIALS AND METHODS: We prospectively recorded fiber data, including type, size, number of uses, laser pulse energy and frequency, and total energy delivered. All fibers were new and purchased off the shelf by staff at each institution. We performed a cost analysis comparing reusable fibers to single use variants. RESULTS: During 541 procedures a total of 37 holmium:YAG optical laser fibers were used, including 21 Laser Peripherals 270 (Laser Peripherals, Golden Valley, Minnesota), 7 Laser Peripherals 365, 4 Lumenis SlimLine™ 200 and 3 Lumenis SlimLine 365 fibers. After stratifying by core size 365 µm core fibers had significantly more uses than 270 µm core fibers (average 23.5 vs 11.3, p < 0.02). By fiber type the mean ± SE number of uses was 12.8 ± 2.44, 3 ± 0.4, 21.3 ± 7.12 and 28.7 ± 6.69 for the Laser Peripheral 270, Lumenis SlimLine 200, Laser Peripherals 365 and Lumenis SlimLine 365, respectively. The total cost savings for reusable fibers vs single use variants was $64,125. CONCLUSIONS: Reusable holmium:YAG optical laser fibers are a more cost-effective option than single use variants. Fibers with a 365 µm core provide more uses than smaller 270 µm variants.

Which efficiency index for urinary stones treatment?

Clinical results in urinary stones management are often reported using the stone-free (SF) rate, which is simple, reproducible and useful to compare techniques or centers. But this index does not take into account costs or patients' quality of life. In a way, SF "pursuit", which cannot be considered as a universal therapeutic goal could increase costs and decrease patients' comfort. We retrospectively reviewed files of stone management to describe costs according to several items and we emphasize the need for a true efficiency index.

[Economic aspects of evidence-based metaphylaxis]. / Okonomische Aspekte der evidenzbasierten Harnsteinmetaphylaxe.

The calculation model which we developed for the cost of stone therapy and metaphylaxis in Germany some years ago with a social health insurance company is based on estimates of stone incidence, types and recurrence rates, actual costs for stone removal, and metaphylaxis (based on data from a district of the social health care system). There are 200,000 stone recurrences per year in Germany. Costs for treatment of these stones amount to $687,000,000. Stone metaphylaxis reduces the recurrence rate by some 40%. The annual cost for stone removal could be lowered by $275,300,000. Metabolic evaluation/metaphylaxis amount to $70,100,000 per year, resulting in a net saving of $205,200,000. In 1997, there were 96 days off work per stone patient resulting in 5,800,000 days off work in Germany per year. Metaphylaxis is not only medically effective in stone formers but also can lower health care cost significantly. Although health care conditions may vary from country to country, in principle this calculation model is applicable also to other countries.

Comparative costs of the various strategies of urinary stone disease management.

New technology is a major determinant of total healthcare costs. The assessment of alternative technologies from a cost-effectiveness perspective is important, although other considerations may finally determine which technology is used. The alternatives of extracorporeal shock wave lithotripsy (ESWL) and percutaneous nephrostolithotomy (PCNL) for the treatment of renal stone disease were compared by studying 1000 cases of ESWL and 133 cases of PCNL using a noncontemporaneous cohort study with PCNL representing the earlier cohort. The effectiveness, defined by success and stone-free rates, was higher with PCNL than with ESWL (96% success vs. 70%); PCNL was also accompanied by a lower burden of additional therapy, whereas ESWL had a higher retreatment rate. From the perspective of a third-party payer, total costs per case of ESWL ($2,746) were lower than those of PCNL ($4,087), but the figure varies with the annual volume. These represent the costs for complete treatment of a patient, including the costs of alternative technology such as PCNL or ureteroscopy that may ultimately be necessary in a patient initially managed by ESWL. The cost for a single ESWL treatment was $2,226 (at a volume of 1000 cases per year), but this increased to $2,746 when costs of retreatment and alternative treatment were prorated to each patient treated. The relative contribution of capital costs to the total cost of ESWL was always less than total professional fees and was only 12% at a volume of 2000 cases/year. Therefore ESWL is less expensive but it is also less effective in rendering patients stone-free.

Idiopathic calcium oxalate urolithiasis: risk factors and conservative treatment.

Idiopathic calcium oxalate urolithiasis is a frequent and recurrent multifactorial disease. This review focuses on urinary and dietary risk factors for this disease and conservative strategies for rectifying them. Dietary oxalate and calcium and their respective urinary excretions have been extensively investigated during the last 10 years. Urinary oxalate has emerged as the most important determinant of calcium oxalate crystallization while the role of urinary calcium has shifted to bone balance and osteoporosis. Dietary calcium restriction increases urinary oxalate and contributes to a negative bone balance. It has therefore been abandoned as a means to reduce the risk of calcium oxalate kidney stone formation. Calcium oxalate kidney stone patients are advised to increase their fluid intake to achieve a urine volume of 2 l or more; the recommended calcium intake is 800-1200 mg/day; high oxalate foods should be restricted; daily protein intake should be between 0.8 and 1 g/kg body weight/day; essential fats should be included; vegetable and fruit (except oxalate-rich vegetables) intake should be increased. The use of calcium supplements has potential benefits but needs to be examined further.

Funding for urolithiasis research: progress and strategies for future NIH support.

A review of the National Institutes of Health funding history for urolithiasis shows that support has increased from about $3 million in 1990 to about $4.7 million in 1993 and to an estimated $5.1 million in 1994. The award of large project grants accounts for the increase: individual research project grant funding (R01-type grants) has not increased. The overall funding for urologic research supported by the National Institute of Diabetes and Digestive and Kidney Diseases has more than doubled in this same period, with most of the increase attributable to the award of individual research grants. Although there has been a significant number of urolithiasis research grant applications submitted in this time period, the percent of successful (funded) applications continues to lag behind the number in other urology-related areas. Strategies for improving the award rate for urolithiasis-related research grant applications are reviewed.

Cost-effectiveness analysis: application to endourology.

A literature review was conducted on the application of economic analysis to clinical medicine, particularly urology. The surgical management of urolithiasis and the treatment of ureteropelvic junction obstruction were used as specific disease examples to evaluate how cost-effectiveness analysis has been used to address the clinical concerns of practicing urologists. As the costs and outcomes of the treatment of kidney stone disease and ureteropelvic junction obstruction can be specifically defined, the application of cost-effectiveness analysis in these two areas meets most standards of economic analysis. Economic models that incorporate poor assumptions, incomplete data, or both are unlikely to have significant clinical utility. The most useful models are those that are structurally simple and evaluate healthcare program alternatives from the patient's, provider's, or society's perspective.

Rates of diseases and their associated costs in two Colorado sheep feedlots (1985-1986).

Data related to rates of disease and their associated costs were collected for 12 months from 2 sheep feedlots in northern Colorado. There was an apparent seasonal occurrence of many of the diseases. Pneumonia, enterotoxemia, acidosis, and transport tetany accounted for most of the diseases seen in these feedlots and were responsible for most of the economic losses. There was a large difference in the incidence of diseases between the 2 feedlots and in the expenditures for disease prevention between the 2 feedlots.

[Socioeconomic aspects of urinary calculi and metaphylaxis of urinary calculi]. / Volkswirtschaftliche Aspekte des Harnsteinleidens und der Harnsteinmetaphylaxe.

A calculation model was developed for the cost of stone therapy and metaphylaxis in Germany based on estimates of stone incidence, types and recurrence rates, actual costs for stone removal and metaphylaxis (based on data from a district of the social health care system). There are 200,000 stone recurrences per year in Germany. Cost for treatment of these stones amount to $687,000,000. Stone metaphylaxis reduces the recurrence rate by some 40%. The annual cost for stone removal could be lowered by $275,300,000. Metabolic evaluation/metaphylaxis amount to $70,100,000 per year, resulting in an net saving of $205,200,000. In 1997, there were 96 days off-work per stone patient resulting in 5,800,000 days off-work in Germany per year. Metaphylaxis in stone formers can lower health care cost significantly. Although health care conditions may vary from country to country, in principle this calculation model is applicable also to other countries.

[Surgical treatmnt for urolithiasis (in view of medical economics)].

Surgical treatment for upper urinary stones has dramatically changed since extracorporeal shock wave lithotripsy (ESWL) was introduced in 1985 in Japan. Since then, the number of ESWL apparatus is increasing year by year, and there were about 800 ESWL apparatus available in Japan in 2001. On the other hand, the number of patients with upper urinary stones are also increasing in Japan, and the age-adjusted annual incidence of first-episode upper urinary tract stones in 1995 was estimated at 68.9 per 100,000 (100.1 in men and 55.4 in women), a steady increase from 54.2 in 1965. Under these circumstances, it would be very important to treat stone patients surgically even from an economical point of view, because the cost of ESWL is very expensive and more than 90% of the patients with urolithiasis are now treated by ESWL. In this paper, the medical economics of urolithiasis in Japan is discussed especially in the surgical treatment.

[Economical aspects on the treatments of urolithiasis by surgical methods: comparison of surgical method selections and world status].

Economical elements including surgical fee and hosipital stay become larger in the selection of surgical methods for the treatment of urinary stones. Then, urologists need to explain to patients the treatment cost to obtain informed consent. By comparing the data from participants' answer to Debate 1 at the 82th annual meeting of the Japanese Urological Association (April 2002, Tokyo) and questionnaire responses from the members of the annual meeting of central division of Japanese Urological Association (November 2002, Nagoya), we surveyed the trends of surgical methods on the treatments of staghorn caliculi and lower ureter stones. Furthermore, we clarified the cost of these methods. Based on the status of world countries, we demonstrate the ideal selection including economical aspects on the selection of endourological method.

[The impact of upper urinary tract stone diseases on the national economy].

The incidence of upper urinary tract stones is increasing, and it is most often seen in persons in the prime of their lives during their most productive years. It must be taken into account that surgical treatment takes them away from their jobs for long periods of time. We therefore should be careful in choosing a treatment modality for a patient. We evaluated extracorporeal shock wave lithotripsy (ESWL), transurethral ureteroscopy (TUL) and open surgery from the viewpoint of national economy and patient amenity. ESWL offered the fewest hospital days and better amenity, though it was the most expensive. ESWL also offered the fewest days missed from work and this could minimize the loss of national economic productivity. We conclude that as a whole, ESWL is the least expensive therapy in terms of national economy compared with TUL and open surgery.

[Percutaneous nephrolithotomy after failure of extracorporeal shockwave lithotripsy. Indications, results, perspectives]. / Néphrolithotomie per-cutanée après échec de lithotritie extra-corporelle par ondes de choc. Indications, résultats, perspectives.

Eighty-one of the 579 extracorporeal lithotripsies (ECL) performed between 1987 and 1992 with an ultrasound-guided hydroelectric lithotriptor required the use of another treatment modality. 53 percutaneous nephrolithotomies (PCNL) were performed in these 81 patients after failure of ECL (21 for non-fragmentation, 32 for residual fragments). The authors analyse the factors responsible for failure in order to select the more appropriate type of treatment for different types of stones. The site of the stones, their size, their radiographic appearance, their chemical composition, the number of ECL sessions and the number of days spent in hospital were compared between the PCNL and ECL groups. Smooth, homogeneous stones denser than bone and larger than 15 mm in diameter were significantly more resistant to ECL, despite an increased number of shock waves. PCNL was successful in 92% of cases of non-fragmented stones (with no residual fragments). The success rate for multiple residual fragments was 64%. In view of the risk of complications associated with residual fragments, regardless of their size, the potential risks of ECL and cost imperatives, the authors recommend that these stones, considered to be resistant, should be treated immediately by PCNL, as the results of PCNL after ECL are less satisfactory.

The impact of unplanned postprocedure visits in the management of patients with urinary stones.

BACKGROUND: Unplanned follow-up care is the focus of intense health policy interest, as evidenced by recent financial penalties imposed under the Affordable Care Act. To date, however, unplanned postoperative care remains poorly characterized, particularly for patients with kidney stones. Our objective was to describe the frequency, variation, and financial impact of unplanned, high-acuity, follow-up visits in the treatment of patients with urinary stone disease. METHODS: We identified privately insured patients undergoing percutaneous nephrostolithotomy, ureteroscopy, or shock-wave lithotripsy for stone disease. The primary outcome was occurrence of an emergency department visit or hospital admission within 30 days of the procedure. Multivariable models estimated the odds of an unplanned visit and the incremental cost of those visits, controlling for important covariates. RESULTS: We identified 93,523 initial procedures to fragment or remove stones. Overall, 1 in 7 patients had an unplanned postprocedural visit. Unplanned visits were least common after shock-wave lithotripsy (12%) and occurred with similar frequency after ureteroscopy and percutaneous nephrostolithotomy (15%). Procedures at high-volume facilities were substantially less likely to result in an unplanned visit (odds ratio 0.80, 95% confidence interval [95% CI] 0.74-0.87, P < .001). When an unplanned visit occurred, adjusted incremental expenditures per episode were greater after shock-wave lithotripsy ($32,156 [95% CI $30,453-33,859]) than after ureteroscopy ($23,436 [95% CI $22,281-24,590]). CONCLUSION: Patients not infrequently experience an unplanned, high-acuity visit after low-risk procedures to remove urinary stones, and the cost of these encounters is substantial. Interventions are indicated to identify and reduce preventable unplanned visits.

[Inpatient therapy of urinary stones in Germany: development of the G-DRG system]. / Harnsteintherapie im stationären Bereich in Deutschland : Entwicklung des G-DRG-Systems.

BACKGROUND: The therapy of urinary stones in Germany is mostly a domain of hospitals even now. With the introduction of the German diagnosis-related groups (G-DRG) system in the years 2003/2004 an attempt was made to realize an ever-increasing fair representation and remuneration of treatment costs. Simultaneously, a declared target was to transfer all forms of treatment which did not necessitate hospital admission to the outpatient department. RESULTS: Analysis of the D-DRG data on running invoicing from all German hospitals from 2004/2005 to 2012/2013 showed an increase in case numbers of around 12% with a parallel increase in the volume of revenues of around 37%. A special feature was a reduction in the proportion of extracorporeal shockwave therapy (ESWL) as inpatient treatment with a parallel increase in the proportion of ureteroscopic and percutaneous interventions.